obesity drug news today glp-1 september 2025 2024 was a record year for trials and is already poised to take over Pharma Giants Bet on Next-Generation
Description
The high cost of GLP-1s is a key factor in this disparity
After 38 weeks of age, mice were randomized within the three cohorts and equally distributed according to body composition
J Immunol Res
Recent phase 1 trial results of the GIP/GLP-1/glucagon triple co-agonist LY3437943 showed promising reductions in body weight and blood glucose as well as a safety profile consistent with those of other incretin-based therapeutic agents in early phases of development 85,86
In the chemical stimulation assay, KCl (60 mM), carbachol (100 M
1.7% with placebo
